Lundbeck's eptinezumab helps build a healthy Greater Bay Area, bringing new hope to migraine patients
Recently, the innovative drug Eptinezumab from Lundbeck for the preventive treatment of adult migraines has officially arrived at Sun Yat-sen Memorial Hospital in the Guangdong-Hong Kong-Macao Greater Bay Area through the "Greater Bay Area Drug and Medical Device Access Policy." Eptinezumab was approved by the U.S. Food and Drug Administration (FDA) in February 2020 for the preventive treatment of adult migraines. It is the first and only monoclonal antibody drug targeting calcitonin gene-related peptide (CGRP) approved by the FDA for intravenous use. This arrival will bring new treatment options for mainland migraine patients in the Greater Bay Area.
Professor Tang Yamei, Vice President of Sun Yat-sen Memorial Hospital and Director of the Neurology Department, Soren Bindesboll, Consul General of the Kingdom of Denmark in Guangzhou, and Jens Hoeyer, General Manager of Lundbeck China (Mainland and Hong Kong), among others, attended the offline event titled "Eptinezumab Empowers a Healthy Greater Bay Area, Bringing New Hope to Migraine Patients."
Caption: Group photo of attendees
Migraine is a common disabling primary headache characterized by recurrent moderate to severe headaches. It often begins in childhood, adolescence, or early adulthood. Studies show that the global annual prevalence of migraine is 14.4%, with 18.9% in women and 9.8% in men. Research reports that migraine significantly disables patients and negatively impacts daily life. It can also coexist with various conditions such as anxiety and depression. A domestic cross-sectional study involving 2,868 adult patients with primary headache disorders from 23 hospitals between September 2020 and May 2021 found that only 16.5% of migraine patients had received preventive medication before the study, indicating inadequate preventive treatment.
"There is still much room for improvement in the treatment of migraine patients in China, such as low consultation rates, low diagnosis rates, and low preventive treatment rates. One reason is the limited availability of innovative preventive drugs for migraines. Preventive treatment can reduce the frequency, duration, and intensity of attacks, helping patients return to normal work and life sooner," Professor Tang Yamei said. "The emergence of innovative preventive treatments targeting CGRP, such as the monoclonal antibody Eptinezumab, has revolutionized migraine diagnosis and treatment. Its mechanism primarily involves specifically binding to CGRP, inhibiting CGRP pathway activity, thereby achieving preventive effects. Eptinezumab requires only one injection every three months, acts quickly, has proven efficacy, and minimal side effects, which also helps improve patient adherence and reduce disease burden. Its arrival in the Greater Bay Area will provide new treatment options for migraine patients, improving their quality of life." Professor Tang Yamei called for increased public education on migraines to raise awareness, emphasize preventive treatment, and improve disease management.
The successful arrival of Eptinezumab in the Greater Bay Area is supported by the "Greater Bay Area Drug and Medical Device Access Policy." This policy, as a key initiative for medical innovation in the Greater Bay Area, aims to accelerate the application of advanced international medical products in the mainland and promote the internationalization and high-quality development of medical services. Since its implementation, Guangdong Province has continuously optimized the policy's hospital admission mechanism for products and expanded its scope.
Jens Hoeyer, General Manager of Lundbeck China (Mainland and Hong Kong), said: "Lundbeck is a global pharmaceutical company focused on neuroscience. In this rapidly evolving therapeutic area, we cover the entire value chain from molecules to patients. Our curiosity, responsibility, and adaptability enable us to promote brain health and transform lives. We aim to address significant unmet needs in brain diseases faster and further. We are delighted that Eptinezumab has arrived in the Guangdong-Hong Kong-Macao Greater Bay Area, marking another milestone in Lundbeck's efforts in migraine treatment in China after its arrival in Boao. We will actively advance Eptinezumab's clinical trials and registration in China to make globally leading innovative treatments more accessible."
Søren Bindesbøll, Consul General of the Kingdom of Denmark in Guangzhou, congratulated the arrival of Eptinezumab in the Greater Bay Area: "We are pleased to see Lundbeck, as a Danish pharmaceutical company, persistently promoting the market access of innovative migraine treatments from Boao Lecheng to the Guangdong-Hong Kong-Macao Greater Bay Area, fulfilling its commitment to promoting brain health and improving the lives of patients with brain diseases in China. Addressing global challenges like migraines requires collective efforts. We commend the Chinese government's significant efforts through pilot policies like the 'Greater Bay Area Drug and Medical Device Access Policy' to provide patients with innovative treatments. We look forward to more Danish companies entering the Chinese market through this platform, benefiting Chinese patients with innovative products and global expertise."
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
